Dysregulation of Miro1 removal kinetics on mitochondria has emerged as a potential common mechanism shared by both sporadic and familial PD pathology, and may therefore represent a novel therapeutic target [122]. This evidence concerns the gene RHOT1 and Parkinson disease.